Heron Therapeutics (HRTX)
NASDAQ:HRTX
Holding HRTX?
Track your performance easily

Heron Therapeutics (HRTX) Ownership - Who Owns Heron Therapeutics?

1,504 Followers

Heron Therapeutics (HRTX) Ownership Overview

5.21%11.70%2.92%9.57%70.60%
2.92% Other Institutional Investors
9.57% ETFs
70.60% Public Companies and
Individual Investors
The ownership structure of Heron Therapeutics (HRTX) stock is a mix of institutional, retail, and individual investors. Approximately 24.19% of the company’s stock is owned by Institutional Investors, 5.21% is owned by Insiders, and 70.60% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 21, 2023
William Forbes
Evp, Chief Development Officer
xxxxxxxxxxxxx
$27250
Nov 20, 2023
William Forbes
Evp, Chief Development Officer
xxxxxxxxxxxxx
$46500
Nov 17, 2023
Craig Collard
Ceo,director
xxxxxxxxxxxxx
$136500
Nov 17, 2023
Ira Duarte
Evp & Cfo
xxxxxxxxxxxxx
$74800

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,196,444Institution5.40%14,753,599
7,038,571Insider4.64%12,669,428
7,002,620Institution4.62%12,604,716
4,711,727Institution3.11%8,481,109
2,992,985Institution1.97%5,387,373
1,598,925Institution1.05%2,878,065
1,545,683Institution1.02%2,782,229
1,304,898Institution0.86%2,348,816
751,073Institution0.50%1,351,931
614,746Institution0.41%1,106,543

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,002,620Institution4.62%12,604,716
2,992,985Institution1.97%5,387,373
1,598,925Institution1.05%2,878,065
1,545,683Institution1.02%2,782,229
1,304,898Institution0.86%2,348,816
614,746Institution0.41%1,106,543
564,684Institution0.37%1,016,431
377,295Institution0.25%679,131
346,624Institution0.23%623,923
238,057Institution0.16%428,503

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,683,800Institution3.09%9,320,762
3,084,020Institution2.03%5,551,236
2,376,436Institution1.57%4,729,108
1,005,927Institution0.66%1,810,669
670,476Institution0.44%1,186,743
538,693Institution0.36%1,071,999
350,353Institution0.23%697,202
284,497Institution0.19%503,560
272,606Institution0.18%490,691
208,705Institution0.14%375,669

FAQ

Who Owns Heron Therapeutics (HRTX)?
According to the latest TipRanks data, approximately 2.92% of the company's stock is held by institutional investors, 5.21% is held by insiders, and 70.60% is held by retail investors.
    What percentage of Heron Therapeutics (HRTX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 2.92% of Heron Therapeutics (HRTX) stock is held by institutional investors.
      What percentage of Heron Therapeutics (HRTX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 70.60% of Heron Therapeutics (HRTX) stock is held by retail investors.
        Who owns the most shares of Heron Therapeutics (HRTX)?
        Vanguard owns the most shares of Heron Therapeutics (HRTX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis